Literature DB >> 7357565

Clinical correlations of steroid receptors and male breast cancer.

R B Everson, M E Lippman, E B Thompson, W L McGuire, J L Wittliff, E R De Sombre, E V Jensen, A Singhakowinta, S C Brooks, J P Neifeld.   

Abstract

Estrogen receptors (ER) were present in tumor specimens from 29 of 34 cases of male breast cancer. There was a significant negative correlation of ER concentration with age. The quantity of ER tended to correlate directly with progesterone receptor levels, disease-free interval, and response duration among responders, but not to a statistically significant extent. In 13 patients for whom response data were available, no significant correlation was observed between ER levels and either frequency or duration of orchiectomy response. Among the six patients with tumor ER levels of less than 30 fmol per mg of protein, however, only two brief responses to orchiectomy occurred that were of little clinical benefit, while three of seven patients with higher ER responded more favorably. Thus, although this suggests that a relationship between low ER and unfavorable orchiectomy response may emerge as more patients are studied, currently available data do not justify basing therapeutic intervention on ER status of a biopsy in a manner analogous to that used for female breast cancer. Nine of 14 male breast cancer patients had positive progesterone receptor assays and several had androgen or glucocorticoid receptors. Tissue from only three of ten men with gynecomastia had measurable ER, and these were limited to the 4S component on sucrose gradients.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7357565

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

Review 1.  Cancer of the male breast: a review.

Authors:  W L Williams; M Powers; L D Wagman
Journal:  J Natl Med Assoc       Date:  1996-07       Impact factor: 1.798

2.  Are there biologic differences between male and female breast cancer explaining inferior outcome of men despite equal stage and treatment?!

Authors:  A-C Müller; C Gani; H M E Rehm; F Eckert; M Bamberg; T Hehr; M Weinmann
Journal:  Strahlenther Onkol       Date:  2012-08-01       Impact factor: 3.621

Review 3.  Estrogen receptor content in malignant breast tumors in men--a review.

Authors:  H Olsson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

4.  Male breast cancer: Austrian experience.

Authors:  M Stierer; H Rosen; W Weitensfelder; H Hausmaninger; B Teleky; R Jakesz; H Fruhwirth; M Dünser; S Beller; A Haid
Journal:  World J Surg       Date:  1995 Sep-Oct       Impact factor: 3.352

Review 5.  Histologic types and hormone receptors in breast cancer in men: a population-based study in 282 United States men.

Authors:  H Stalsberg; D B Thomas; K A Rosenblatt; L M Jimenez; A McTiernan; A Stemhagen; W D Thompson; M G Curnen; W Satariano; D F Austin
Journal:  Cancer Causes Control       Date:  1993-03       Impact factor: 2.506

6.  Breast cancer in a man treated effectively with a large dose of tamoxifen citrate.

Authors:  H Okamoto; M Nishiki; N Takeichi; M Yamane; T Matsuyama; K Dohi
Journal:  Jpn J Surg       Date:  1986-11

7.  Proliferative activity is a significant prognostic factor in male breast carcinoma.

Authors:  A Pich; E Margaria; L Chiusa
Journal:  Am J Pathol       Date:  1994-08       Impact factor: 4.307

8.  Androgen receptor expression in male breast carcinoma: lack of clinicopathological association.

Authors:  A Pich; E Margaria; L Chiusa; G Candelaresi; O Dal Canton
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

9.  Role of aminoglutethimide in male breast cancer.

Authors:  A L Harris; M Dowsett; R Stuart-Harris; I E Smith
Journal:  Br J Cancer       Date:  1986-10       Impact factor: 7.640

10.  The sex hormone profile of male patients with breast cancer.

Authors:  D Nirmul; R J Pegoraro; I Jialal; C Naidoo; S M Joubert
Journal:  Br J Cancer       Date:  1983-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.